<DOC>
	<DOCNO>NCT02317042</DOCNO>
	<brief_summary>This study evaluate efficacy new therapy ( Automatic Expiratory Positive Airway Pressure intelligent Volume Assured Pressure Support ( AutoEPAP iVAPS ) ) design treat respiratory insufficiency , respiratory failure and/or nocturnal hypoventilation upper airway obstruction . The study perform two phase : In sleep unit home environment . The new therapy compare two exist ventilator therapy : `` Spontaneous Timed ( ST ) mode '' `` Intelligent Volume Assured Pressure Support ( iVAPS ) '' .</brief_summary>
	<brief_title>Juno Perth Clinical Trial</brief_title>
	<detailed_description>Phase I : To compare sleep sleep-breathing parameter patient use AutoEPAP iVAPS ( experimental arm ) compare iVAPS ( commercially available therapy ) Participants already establish non-invasive ventilation ( NIV ) recruit participate 3 night monitor sleep unit . They sleep study night : Night 1 involve evaluation current NIV setting . Some setting use set AutoEPAP iVAPS iVAPS . Night 2 &amp; 3 : participant randomise AutoEPAP iVAPS iVAPS . They sleep study therapy , whereby sleep sleep-breathing monitor evaluate . After night , participant ask complete questionnaire well sleep . Phase II : To compare sleep-breathing therapy adherence patient use AutoEPAP iVAPS ( experimental arm ) compare usual therapy ( Spontaneous Time ( ST ) mode ) . Participants already establish non-invasive ventilation ( NIV ; ie . ST mode ) recruit participate 14 night . This study occur home . The participant randomise trial AutoEPAP iVAPS ST mode therapy Week 1 2 . Data collect onto respiratory device ( i.e . Juno ) detail objective usage , air leak breathing parameter ( e.g . oxygenation ) . Participants also complete questionnaire week evaluate subjective sleep quality comfort . Blood sample also collect Pre-week 1 , week 1 &amp; 2 measure oxygen , carbon dioxide bicarbonate level blood . Blood sample take ear lobe .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Respiratory Insufficiency</mesh_term>
	<mesh_term>Pulmonary Valve Insufficiency</mesh_term>
	<mesh_term>Hypoventilation</mesh_term>
	<mesh_term>Airway Obstruction</mesh_term>
	<mesh_term>Neuromuscular Diseases</mesh_term>
	<mesh_term>Obesity Hypoventilation Syndrome</mesh_term>
	<criteria>Patient COPD , Obesity Hypoventilation Syndrome Neuromuscular disease hypercapnia Clinically establish bilevel therapy least 3 month prior recruitment Uses &lt; 4 L/min oxygen therapy Participant provide informed consent Patient noncompliance bilevel therapy ( ie . &lt; 4 hr/night ) Patient severe asthma , Patient pregnant Patient require Participant tracheostomy Participant acutely ill , medically complicate medically unstable Participants PAP therapy otherwise medically contraindicate Participant surgery upper airway , nose , sinus , middle ear within previous 90 day recruitment Participant untreated , nonobstructive sleep apnea ( OSA ) sleep disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>